[6] Psyllium reduces LDL-C by 0.33 mmol/l (12.5 mg/dl) and also reduces apolipoprotein B, leading one systematic review to conclude that it "effectively improves conventional and alternative lipids markers, potentially delaying the process of atherosclerosis-associated CVD risk in those with or without hypercholesterolemia".
[8] There are two sources of cholesterol in the upper intestine: dietary (from food) and biliary (from bile).
Once absorbed by the enterocyte, cholesterol is reassembled into intestinal lipoproteins called chylomicrons.
Managing cholesterol at the site of absorption is an increasingly popular strategy in the treatment of hypercholesterolemia [citation needed].
For statin-resistant or statin-sensitive populations that are characterized by low one-year compliance rates, such a combination therapy is proving to be especially effective [citation needed].